Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.92 +2.3%	$186.85	$163.52 ▼ $218.66	$327.88B	0.48	6.23 million shs	5.94 million shs
ABT Abbott Laboratories	$136.21 +0.1%	$133.03	$99.71 ▼ $141.23	$236.64B	0.73	6.13 million shs	5.34 million shs
AZN AstraZeneca	$71.46 +2.3%	$70.72	$61.24 ▼ $87.68	$216.72B	0.37	5.21 million shs	6.73 million shs
MRK Merck & Co., Inc.	$81.75 +3.3%	$79.14	$73.31 ▼ $129.93	$198.77B	0.39	13.15 million shs	21.80 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+2.22%	+2.36%	+2.37%	-7.32%	+11.48%
ABT Abbott Laboratories	+0.09%	-1.39%	+1.89%	+3.11%	+31.99%
AZN AstraZeneca	+2.26%	+1.30%	-1.87%	-1.05%	-8.31%
MRK Merck & Co., Inc.	+3.23%	+1.71%	+6.36%	-5.61%	-36.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9433 of 5 stars	3.4	5.0	4.2	3.9	2.9	1.7	1.3
ABT Abbott Laboratories	4.8991 of 5 stars	2.4	3.0	4.2	4.5	2.9	2.5	2.5
AZN AstraZeneca	2.3131 of 5 stars	2.4	3.0	1.7	0.0	3.0	0.0	1.3
MRK Merck & Co., Inc.	4.9956 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.25% Upside
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	4.70% Upside
AZN AstraZeneca	2.83	Moderate Buy	$85.00	18.95% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	33.56% Upside

Current Analyst Ratings Breakdown

Latest AZN, MRK, ABT, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.96	$15.28 per share	12.43	$1.90 per share	99.96
ABT Abbott Laboratories	$41.95B	5.65	$6.59 per share	20.66	$27.62 per share	4.93
AZN AstraZeneca	$54.07B	4.10	$6.44 per share	11.10	$13.18 per share	5.42
MRK Merck & Co., Inc.	$64.17B	3.20	$9.78 per share	8.36	$18.33 per share	4.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.82	13.59	1.23	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
ABT Abbott Laboratories	$13.40B	$7.71	17.67	23.77	2.58	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.70	14.29	1.28	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.90	8.26	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)

Latest AZN, MRK, ABT, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/24/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	N/A	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.45%	N/A	279.15%	53 Years
ABT Abbott Laboratories	$2.36	1.73%	N/A	30.61%	54 Years
AZN AstraZeneca	$2.06	2.88%	N/A	82.73%	N/A
MRK Merck & Co., Inc.	$3.24	3.96%	N/A	47.16%	14 Years

Latest AZN, MRK, ABT, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
ABT Abbott Laboratories	0.26	1.78	1.27
AZN AstraZeneca	0.65	0.90	0.70
MRK Merck & Co., Inc.	0.69	1.41	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
MRK Merck & Co., Inc.	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable

AZN, MRK, ABT, and ABBV Headlines

Recent News About These Companies

Vontobel Holding Ltd. Decreases Position in Merck & Co., Inc. (NYSE:MRK)

1 hour ago | marketbeat.com

Trading Rotation Kicks Off 2nd Half of 2025

July 1 at 7:11 PM | zacks.com

Dividend Yield Theory Says Merck Is A Buy

July 1 at 3:11 PM | seekingalpha.com

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

July 1 at 1:10 PM | zacks.com

Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai

July 1 at 8:49 AM | businesswire.com

Summit Trail Advisors LLC Increases Stake in Merck & Co., Inc. (NYSE:MRK)

July 1 at 8:47 AM | marketbeat.com

Sumitomo Mitsui DS Asset Management Company Ltd Has $50.14 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

July 1 at 8:47 AM | marketbeat.com

BLB&B Advisors LLC Sells 3,392 Shares of Merck & Co., Inc. (NYSE:MRK)

July 1 at 8:09 AM | marketbeat.com

Mather Group LLC. Acquires 16,721 Shares of Merck & Co., Inc. (NYSE:MRK)

July 1 at 7:24 AM | marketbeat.com

Alta Advisers Ltd Acquires 4,200 Shares of Merck & Co., Inc. (NYSE:MRK)

July 1 at 7:05 AM | marketbeat.com

Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

July 1 at 7:02 AM | businesswire.com

9,491 Shares in Merck & Co., Inc. (NYSE:MRK) Acquired by Unified Investment Management

July 1 at 6:47 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Smith Salley Wealth Management

July 1 at 6:29 AM | marketbeat.com

Ameritas Advisory Services LLC Has $3.11 Million Position in Merck & Co., Inc. (NYSE:MRK)

July 1 at 5:18 AM | marketbeat.com

7,162 Shares in Merck & Co., Inc. (NYSE:MRK) Bought by G&S Capital LLC

June 30 at 9:17 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Essex LLC

June 30 at 9:16 AM | marketbeat.com

Red Door Wealth Management LLC Acquires 8,717 Shares of Merck & Co., Inc. (NYSE:MRK)

June 30 at 8:55 AM | marketbeat.com

Insight Inv LLC Buys 14,987 Shares of Merck & Co., Inc. (NYSE:MRK)

June 30 at 8:18 AM | marketbeat.com

Argent Advisors Inc. Acquires 4,029 Shares of Merck & Co., Inc. (NYSE:MRK)

June 30 at 7:58 AM | marketbeat.com

Red Cedar Investment Management LLC Sells 10,004 Shares of Merck & Co., Inc. (NYSE:MRK)

June 30 at 7:50 AM | marketbeat.com

Canandaigua National Bank & Trust Co. Raises Stake in Merck & Co., Inc. (NYSE:MRK)

June 30 at 7:49 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN, MRK, ABT, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$189.92 +4.30 (+2.32%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$190.94 +1.03 (+0.54%)

As of 06:35 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$136.21 +0.20 (+0.15%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$137.24 +1.02 (+0.75%)

As of 06:40 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$71.46 +1.58 (+2.26%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$71.23 -0.23 (-0.32%)

As of 06:33 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$81.75 +2.59 (+3.27%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$82.10 +0.35 (+0.43%)

As of 06:39 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time